Life Sciences Investing
Rod discusses the current state of the biotech market, highlighting that we are experiencing the second worst correction in the industry's history. Despite the challenges, he emphasizes the unprecedented innovation boom driven by cheaper access to genomic information and a surge in drug development modalities. This combination positions the sector for potential growth, even amid current low valuations.In this clip
From this podcast
Capital Allocators – Inside the Institutional Investment Industry
Rod Wong – Empty Rooms: Innovation in Biotech at RTW (Capital Allocators, EP. 310)
Related Questions
What are the most promising biotech breakthroughs?
What are current advancements in biotechnology, including insights from the episode Moderna: The Software of Life - \[Business Breakdowns, EP. 13] and the clip Biotech Company Evolution?
Can venture investing lead to innovation in the context of the episode Drugging the Undruggable with Greg Verdine and the clip Innovation in Biotech?